Ipilimumab vs Nivolumab

## Ipilimumab vs Nivolumab: Overview

This comparison examines the pharmacological differences between **Ipilimumab** and **Nivolumab**.

## Mechanism of Action

**Ipilimumab**: Fully human anti-CTLA-4 IgG1 monoclonal antibody that blocks CTLA-4 inhibitory signaling.

**Nivolumab**: Fully human anti-PD-1 IgG4 monoclonal antibody restoring T-cell anti-tumor activity.

## Pharmacokinetics

**Half-life**: Ipilimumab — 14.7 days; Nivolumab — 27 days.

## Chemical Properties

**Type**: Ipilimumab — Antibody; Nivolumab — Antibody.